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have been developed and have provided new insights, particularly focussing on the study of protein-ligand
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G protein-coupled receptors (GPCRs), the largest group of
membrane receptors (~800 in humans), are encoded for by 1% of
the open reading frames (ORFs) of the genomes of higher eukaryotes.
GPCRs are seven transmembrane helix proteins, connected by three
1463S. Tapaneeyakorn et al. / Biochimica et Biophysica Acta 1808 (2011) 1462–1475intracellular and three extracellular loops (Fig. 1). GPCRs are activated
by a wide range of stimuli, including hormones, neurotransmitters,
ions, odorants, and photons of light [1]. The GPCR superfamily is
involved in a variety of biological and pathological processes such as
development and proliferation [2], neurological disorders [3], angio-
genesis [4], metabolic disorders [5], and immune system and
inﬂammation [6]. Consequently, they are one of the largest classes
of drug targets to which agonists and antagonists are currently
focused. Although approximately 50% of pharmaceuticals target
GPCRs, only 10% of the GPCRs, excluding olfactory receptors are
targeted by marketed drugs, indicating the possibility that the
remaining 90% of GPCRs are available as targets for the treatment of
human disease [7].
Based on protein sequence similarity, GPCRs are commonly
divided in three distinct families, A, B and C [8,9], but further divisions
can be used, depending on the criteria used. For instance, Fredriksson
and colleagues have proposed two more families of GPCRs, frizzled/
smoothened-like and adhesion-like families on the basis of phyloge-
netic criteria [10]. All receptors in each family share ≥20% sequence
identity and N40% similarity within the seven-transmembrane
domains. Family A (rhodopsin-like receptors) comprises approxi-
mately 180 liganded GPCRs, 110 orphan GPCRs and approximatelyFig. 1. Homology models based on the limited number of GPCR crystal structures are now
model (top view) of NTS1 based on the crystal structures of turkey β1 adrenergic receptor (P
an extra small helix (VIII) in the intracellular side and a conserved disulﬁde bridge (C142–C22
residues putatively involved in the binding of neurotensin ligand are indicated by black circl
in blue.350 olfactory GPCRs, encompassing more than 80% of total GPCRs.
Most clinically used pharmaceuticals which target GPCRs are directed
at this family [1,11].
It is generally accepted that GPCRs can exist as dimers or as part of
larger oligomeric complexes [12], indeed the dimeric form of some
receptors has been recently reported [13,14]. However, many studies
support monomeric GPCRs as functional units [15–17] and the area is
still highly controversial [18].
Structural studies of GPCR-ligand interactions are still challenging
due to the difﬁculty of functional GPCR production and receptor
stability. To date, only ﬁve inactivated GPCR structures (bovine and
squid rhodopsins, β1AR, β2AR, and A2aR) have been resolved at high
resolution by X-ray crystallography [19–23]. All resolved structures
belong to GPCR class A family. These structures show extensive
similarity consisting of seven transmembrane spans, an extra small
helix on the intracellular side of the membrane and a conserved
disulﬁde bridge (Fig. 1). The structural divergence arising in the
extracellular and intracellular regions are likely to result in their
speciﬁcity of ligand binding and G-protein coupling, respectively.
However, despite their importance, the function of these loops is still
in debate and can be difﬁcult to resolve structurally. The rhodopsin
receptors are activated by light incident on the covalently boundbeing constructed to guide biophysical studies. As an example here, A: a 3D structural
DB ID: 2VT4) and squid rhodopsin (PDB ID: 2Z73): seven transmembrane spans (I–VII),
5, black sticks) (S. Tapaneeyakorn, unpublished data). B: a 2D structural model of NTS1:
es and the N-terminal segment (residues 45–60), important in ligand binding, is shown
Fig. 2. Structural changes ofβ2ARby formoterol. A: the overlay STD-ﬁlteredHMQC spectra
of unliganded β2AR (black), agonist formoterol-bound β2AR (green) and inverse agonist
carazolol-bound β2AR (red). B: a structural model of β2AR activation by formoterol.
Coloured helices, loops and side chains represent the carazolol-bound crystal structure.
Grey helices and white side chains indicate the active-state model. Green sticks indicate
formoterol and yellow indicates the extracellular loop 2. Adapted from [36] with
permission from Copyright owners.
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GPCRs, but none of these latter receptors were crystallised with their
native peptide ligands.
Mutagenesis studies have shown that nonpeptide agonists/
antagonists interact within the transmembrane segments, whereas
peptide ligands bind at the interface between the transmembrane
sections and the extracellular loops [24–27]. Therefore, it has been
suggested that the binding site of nonpeptide agonists/antagonists to
a receptor is different from that of peptide ligands [28]. It is still
unclear whether the GPCR-bound conformation of a peptide is
structurally related to nonpeptide agonists and antagonists. Peptide
ligands bound to receptors belonging to the same family may have
different structures, indicating receptor selectivity and speciﬁcity of
the ligands. The conformation of bound ligand is important for
rational drug design for the treatment of diseases caused by GPCR
malfunctions. Most GPCR-targeted drugs to date are nonpeptide
mimics — they are seldom able to mimic the interactions required to
induce a full peptide ligand signal with selectivity, and consequently
patients have several side effects from taking these drugs [29,30].
There are many attempts to determine receptor-bound and unbound
conformations of peptide ligands in order to understand the
differences in receptor binding and activation, with consequences
for rational drug design.
Here, the use of NMR spectroscopy for GPCR studies will be
presented, including its beneﬁts and limitations. A description of
general solution- and solid-state NMR techniqueswill be also given. In
addition, this review will provide guidelines for new researchers who
are interested in working on GPCRs, especially with protein-ligand
interactions. An overview of expression systems and sample environ-
ments to study GPCRs, and their interactions with ligands will be
presented, speciﬁcally focused towards NMR studies.
2. NMR studies of G protein-coupled receptors
Currently, there are three major approaches, X-ray crystallogra-
phy, solution-state NMR (solNMR) and solid-state NMR (SSNMR), to
study protein-ligand interactions at atomic resolution. Although X-ray
crystallography is the method of choice for large molecules, it
presents some signiﬁcant difﬁculties, for example, producing crystals
and obtaining good diffraction, and mostly provides only a static view
of inherently dynamicmolecules. NMR-basedmethods have therefore
become more important in the study of protein-ligand interactions.
These NMR approaches can be applied to weak and transient protein-
ligand complexes that are difﬁcult to study by other structural
methods [31]. NMR also allows measurement of macromolecular
motions at near-atomic resolution, but motions on a variety of time
scales and amplitudes, which are essential in providing functional
information, are not well understood. In addition, proteins can be
studied in a variety of environments, such as different buffer
conditions, detergentmicelles or bicelles, oriented bilayers, or crystals
[32–35]. However, it should be noted that solNMR and SSNMR
techniques have been used to date to address speciﬁc questions,
rather than to resolve three-dimensional GPCR structures [36–38],
even though this potential exists. For example, the activation of the β2
adrenergic receptor (β2AR) by formoterol induces solNMR spectral
changes of [13C]methyl-β2AR, allowing some limited titrationwhich is
interpreted as conformational changes in helices 6 and 7 (Fig. 2) [36].
NMR linewidths, an important factor for NMR data analysis, are
normally proportional to the tumbling rate (τc−1), so large molecules
which have slow tumbling rates (τc−1 ~0.75 kT/πr3η, where r=molec-
ular radius and η=viscosity)will give large linewidths, which preclude
structural analysis. In solNMR, themolecule needs to tumble rapidly and
isotropically in solution on the NMR time scale (~10−1–10−6 s). Thus,
all orientational information is lost as a consequence of isotropic
tumbling, but fast tumbling averages dipolar interactions to zero and
chemical shifts to isotropic values, resulting in sharp NMR resonances.Although transverse relaxation optimised spectroscopy (TROSY) and
deuteration techniques provide the possibility to study biomolecules
with sizes exceeding a molecular mass of 100 kDa by solNMR [39,40],
traditional solNMR is of limited use for structural studies on large
proteins, membrane proteins and solid materials, because long
correlation times or restricted motions result in incomplete averaging
of the anisotropic interactions leading to the broadened spectrum. Also,
in the case of membrane proteins, it is generally difﬁcult to keep these
proteins active at high concentration at room temperature for the
experimental time required to gain spectra with high signal-to-noise
ratio and resolution. SSNMR can overcome these averaging limitations
to provide structural and dynamic information on proteins and their
bound ligands [41,42]. The technique is designed to elucidate structural
parameters of slowly tumbling or solid-phase samples at atomic
resolution. It is also useful for orientational studies, and has no
theoretical limit of size [41,42].
Unlike solNMR, the resolution and sensitivity of SSNMR are
affected by the size and orientation-dependence of the nuclear spin
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heteronuclear dipolar spin–spin couplings. These interactions are not
averaged to zero, usually generating line-broadening for resonance
SSNMR spectra of a static sample. Sample orientation or high spinning
of a sample at the magic angle spinning (MAS), together with isotopic
labelling, can improve both resolution and signal-to-noise ratio.
SSNMR has been developing rapidly for in particular, the study of
membrane proteins and other non-soluble or large biological
molecules, since crystals and rapid isotropic tumbling are not
necessary. It has the potential to gain accurate internuclear distances
and orientations which give information about molecular struc-
tures [43]. SSNMR has been employed to provide structural and
mechanistic insights of many membrane proteins including GPCRs,
reviewed [44–46], for example rhodopsin [37,47], H1 receptor [38],
sensory rhodopsin II [48], bacteriorhodopsin [49–52], and phage-coat
proteins [53–55].
3. General solution- and solid-state NMR techniques
Nuclear overhauser effect (NOE) related experiments for solution
samples provide structural information of protein and a high-afﬁnity
protein-ligand complex, orientations of the binding domain and
dynamic information of protein-ligand interactions. Assignments of
each resonance in the 1H NMR spectrum are required for NOE-related
experiments. Since the strength of the NOE is proportional to the
internuclear distance (r−6) between two nuclear spins, each cross-
peak in the NOE experiment can be converted in to a maximum
distance between the nuclei, usually closer than ~5 Å. However, a
distance range, rather than a precise value is usually used because the
intensity-distance relationship may not be precise due to local
dynamics.
In contrast to the NOE, transferred nuclear overhauser effect
(trNOE) is the method of choice for the study of low-afﬁnity binding
of ligands to protein. However, the conformation of protein-boundFig. 3. A superposition of 1H/15N-HSQC spectra for Sem-5 C-SH3 in the absence (green cont
ligand binding are indicated by blue arrows (adapted from [65] with permission from Copyligands can only be determined if the dissociation constant (off-rate)
of the ligand from the protein is faster than the longitudinal relaxation
rate of the magnetisation of the peptide. The easy execution of trNOE
experiments has made it a very popular approach in the past decade
[56–58]. Structural information from trNOE experiments can be
extended by the measurement of residual dipolar couplings in terms
of binding geometries [59].
There are several NMR-based methods to determine the location
of ligand binding sites and to extract structural information of a ligand
in complex with a protein. Protein-ligand interactions induce changes
in a variety of NMR parameters, such as chemical shifts, relaxation
parameters, dynamic parameters, diffusion coefﬁcients, saturation
transfer differences, and transfer NOEs. Therefore, these parameters
can be used as indicators of the interactions (for detailed reviews see
[60–62]). For instance, strong association of the ligand with the
protein usually leads to chemical shift changes of both protein and
ligand (see example in Fig. 3) [63–65]. Also, as linewidth is directly
related to apparentmolecular weight, if a small ligand binds a protein,
its linewidth will broaden [66,67]. These two parameters are most
commonly used for probing protein-ligand interactions, providing
information about residues involved in interactions, and as a tool for
ligand screening in drug discovery [68,69].
The observed interactions from chemical shift perturbations can be
conﬁrmed by more precise methods, such as distance measurements.
Precise structures at the binding site can be obtained from intra or
internuclear distances. As mentioned earlier, MAS has been developed
to overcome the problems of analysis of broad spectra of non-
isotropically, quickly tumbling samples [70,71]. The basic principle is
to spin the sample rotor at 54.7° (the magic angle) with respect to the
static ﬁeld B0. There are two commonly applied techniques which use
MAS combined with recoupling methods in order to get distance
information. The ﬁrst is rotational resonance (RR), which is used to
measure the homonuclear dipolar coupling between spin½ pairs such
as 13C–13C and 1H–1H pairs [72,73]. The second technique, rotationalours) and presence (red contours) of peptide. Signiﬁcant chemical shift changes upon
right owners).
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dipolar coupling between spin ½ pairs such as 13C–15N and 13C–19F
pairs [74].
These techniques have been employed for structural determina-
tion of several proteins. For instance, 13C–13C RR and 13C–19F REDOR
techniqueswere employed to investigate themolecularmechanism of
transmembrane signalling of the serine bacterial chemoreceptor upon
ligand binding [75,76]. The RR experiments were also used tomeasure
the distance between the positively charged nitrogen and the
carbonyl once the uniformly labelled acetylcholine bound to the
nicotinic acetylcholine receptor. A distance of 5.1 Å was measured
indicating a bent conformation of bound acetylcholine [77]. If the
spectrum is dominated by natural abundance background from buffer,
lipids or large receptor molecules, the problem can be resolved by
introducing double quantum ﬁltering techniques (Fig. 4), for example
C7 [78], POST-C7 [79], INADEQUATE [80], and R1426 [81]. The one
drawback for site-speciﬁc spin labelling for distance measurements is
the low signal intensity compared to natural abundance of the same
spin type in the system. However, the potential use of a nitroxide spin
label has been recently explored to enhance the NMR signal through
dynamic nuclear polarisation (DNP) [82–84].
4. Isotope labelling
Assignments and sensitivity enhancement can be achieved through
chemically directed isotropic labelling. Additionally, label selection
will be determined by the questions being addressed about structure
and dynamics of proteins, for both solNMR and SSNMR spectroscopy.
Assignment of resonances can be made for homonuclear and/or
heteronuclear spectra depending on labelling strategies and available
NMR samples, for example, homonuclear 2D spectra for unlabelled
proteins, 15N heteronuclear spectra for 15N labelled proteins, or triple
resonance spectra for 15N/13C doubly labelled proteins.
NMR signals from protons, as well as 13C and 15N (spin=½) are
commonly detected in biological NMR assignments from solNMRFig. 4. 1D 13C spectra of uniformly 13C, 15N labelled neurotensin ligand in detergent buffer (5
(red trace) and without (black trace) double quantum ﬁlter (INADEQUATE). INADEQUA
(S. Tapaneeyakorn, unpublished data).experiments. However, in proton detection considerable difﬁculties
are encountered in SSNMR since strong dipolar couplings
(~100 kHz) between protons give rise to structureless broad lines,
even when using sophisticated resolution enhancement techniques
combined with fast (N50 kHz) MAS of the high magnetic ﬁeld. Since
13C and 15N nuclei have smaller dipolar couplings (~10 kHz) and
larger chemical shift range (~200 ppm) than 1H nucleus, they give
rise to much better resolved spectra. Therefore, they are the nuclei
of choice for detection in SSNMR experiments [85]. In these cases,
cross polarisation (CP) from 1H to less sensitive nuclei helps to
enhance sensitivity [86].
Quadrupolar nuclei (spinN½), such as 19F, 31P and 2H for example,
are less-common nuclei for NMR studies of biological molecules.
However, the sensitivity of 19F and 31P is very high as they have 100%
natural abundance leading to a lack of background signals. Natural
isotope labelling with 31P is useful for the studies of GPCR-lipid or
ligand-lipid associations [87–89]. Deuterium, 2H, has such a low
natural abundance and a short longitudinal relaxation time so
deuterium detection is not routine in traditional NMR experiments.
However, deuterium labelling does increase the resolution and
sensitivity in multidimensional NMR experiments and deuterated
solvents are often used to avoid solvent-signal interference in the
proton spectrum (reviewed in [90]). In SSNMR, it is still unclear
whether deuteration has any effect on spectral linewidths of proteins
as a limited number of studies have revealed inconsistent results
[49,91,92] and none have been reported for GPCRs.
A peptide ligand and protein can be isotopically labelled in two
different ways, either uniform or selective/speciﬁc labellings, depend-
ing on the purpose of the experiment. Normally, selective isotope
labelling iswidely used to aid assignment and structure determination
of large proteins because it reduces unwanted peaks and decreases the
spectral crowding. In addition, site-speciﬁc labelling of spin pairs can
be selectively detected for addressing a speciﬁc question of interest.
There are two major methods for producing isotopically labelled
materials, solid-phase peptide synthesis (SPPS) and expression (see0 mM Tris–HCl, pH 7.4, 20 mM KCl, 1% DDM/0.01% CHS, 1 mM EDTA, 5% glycerol) with
TE suppresses signals from natural abundance and results in anti-phase line shapes
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sequences, so it has been widely used for the synthesis of small
peptides and proteins including labelled peptide GPCR-ligands
[64,93,94]. The beneﬁt of SPPS is that highly speciﬁc local information
can be obtained through judicious labelling strategies, where uniform
labelling may not yield such speciﬁcity due to spectral overlap [72].
However, labelled amino acids are very expensive for the SPPS
method which requires necessary protection of reactive groups (for
example Fmoc and Pbf protection of α-amino and side-chain amino
groups of Arg, respectively) and can be wasteful of labelled materials.
Therefore, an expression system is the method of choice when
generating labelled samples in high yield in a cost effective manner,
using more economic 15N and/or 13C sources, particularly for large
biomolecules.
4.1. Comparisons of expression systems
A large amount (0.1–5 mg in ~100–300 μl) of a GPCR is required for
NMR studies. With the notable exception of rhodopsin, GPCRs are
generally expressed at low levels in their endogenous environment.
Therefore, it has been necessary to develop heterologous expression
systems to achieve the high yields of protein. Incorporation of isotopic
labels into the receptor is an additional requirement for performing
target-based NMR experiments, and the process can be easier in some
systems than others. A number of reviews in the past few years have
focused on expression systems for GPCRs in detail [95,96]. Here, we aim
to give an overview of the different systems and to focus on their
application to produce samples suitable for NMR analysis. The same
systems can obviously also be used to produce labelled peptide ligands.
4.2. Escherichia coli
E. coli is an extremely well-established system for heterologous
protein production. Despite numerous advantages (Table 1), there has
been a very low success rate of expressing GPCRs in E. coli. The most
likely explanations for the problems encountered result from the fact
that E. coli is a prokaryote whereas all identiﬁed ligand binding GPCRs
are eukaryotic. Some of the key limitations are outlined in Table 1.
Although these problems may appear daunting, there have been a
number of successes in producing functional GPCRs in E. coli [97–103].
Many of these studies have adopted the use of fusion proteins to
increase the solubility of the overall protein and to help to orientate it
in the E. colimembrane. For example, receptors can be fused to the C-
terminus of E. coli maltose binding protein (MBP) in which the signal
peptide of MBP acts to direct the EC1 loop of the GPCR to the
periplasm [104–106]. Additionally, fusion of a soluble protein such as
thioredoxin to the C-terminus of the GPCR can assist in expres-
sion [105,106]. Such fusion proteins can be cleaved from the
expressed and puriﬁed GPCR by the inclusion of judicious protease
sites. However, expression of functional GPCRs in E. coli typically
involves a “trial and error” procedure in which different fusions
should be investigated and induction conditions varied to balance
active protein production with culture volume and viability.
Despite these successes, the expression levels of GPCRs in E. coli are
still relatively low compared to those desirable for biophysical studies,
although this is partly mitigated by the scalability of E. coli. It should
be noted, however, that there is not necessarily a linear relationship
between culture volume and yield of active protein. One of the highest
yields reported is that of neurotensin receptor 1 (NTS1) (~800 μg of
active receptor per litre of culture), but this is still below the desired
mg per litre levels [105].
Once a GPCR has been expressed in E. coli, this does provide the
advantage that isotopic labelling is extremely well developed. For
example, minimal media recipes allow uniform labelling with 15N
using ammonium salts, 13C using glucose or glycerol and 2H using
deuterated water. It should be noted that in the majority of cases,protein yield per litre of media and/or gram of wet cell pellet drops
signiﬁcantly (can be b20%) when E. coli strains are grown in labelled
minimal media. It is therefore desirable to maximise expression levels
both for factors of scale and cost.
A variety of approaches have been adopted to increase the yield in
minimal labelled media. These include addition of fresh labelled
nutrients upon induction [107] or growth in unlabelled media prior to
induction followed by harvesting and resuspension in labelled media
upon induction [108]. It should be noted that deuteration can be
difﬁcult to achieve due to the inability of some strains to grow on D2O.
Therefore, a process of adaptation is often conducted in which cells
are grown on increasing concentrations of D2O up to N90%. Once cells
have been adapted they can be stored as glycerol stocks [109]. This
adaptation may not, however, be required as certain strains are
capable of immediate growth on N90% D2O.
Additionally, it is possible to label speciﬁc amino acids by including
their isotopic variants in minimal media recipes. It is important to
consider the biosynthetic pathways of E. coli as some steps are
bidirectional (e.g. C2 metabolism) and may result in unwanted
incorporation of labels [109]. It is also possible to use E. coli mutant
strains which lack the biosynthesis genes for the amino acid of
interest, hence ensuring incorporation of the labelled residues.
Processes used for incorporation of labelled amino acids can also be
applied for the incorporation of non-natural amino acids such as
ﬂuorinated derivatives. More complex labelling strategies include
site-speciﬁc backbone deuteration. This can be achieved by synthesis
of a particular 15NH–Cα–2H amino acid which is then incorporated
into recombinant proteins using an appropriate auxotrophic E. coli
strain [109,110]. It is also possible to deuterate speciﬁc amino acid
side chains by incorporation of modiﬁed amino acids or by addition of
appropriately labelled precursors. Other strategies include labelling of
speciﬁc amino acids in a perdeuterated background, selective
complete amino acid protonation and selective methyl group
protonation which are comprehensively reviewed elsewhere
[109,111].
4.3. Yeast
Yeast provides an attractive host for heterologous expression of
GPCRs. The advantages and disadvantages are detailed in Table 1.
Three yeast species form the backbone for heterologous protein
expression. Pichia pastoris can be cultured to a high cell density and
possesses expression systems which can be controlled by methanol. A
recent study has optimised expression of a number of GPCRs in P.
pastoris [112]. Expression in Saccharomyces cerevisiae can be con-
trolled by galactose induction andmany GPCRs have been functionally
expressed in engineered S. cerevisiae strains [113], although not
necessarily at levels which would enable puriﬁcation of sufﬁcient
quantities for biophysical studies. Finally, Schizosaccharomyces pombe
has expression vectors which can be controlled by thiamine and can
express functional heterologous GPCRs [114,115], although there are
no reports to date of puriﬁcation of functional heterologous receptors
from this system.
The combination of a number of strategies is often required for
isolation of large amounts of active receptor. As an example, S.
cerevisiae has been optimised as a host for high-level expression of the
human A2a adrenoceptor. Although functional coupling of this
receptor to the signalling pathway in modiﬁed yeast cells has been
reported [116], a combination of a variety of developments was
necessary to produce sufﬁcient protein levels for biophysical study
[117]. The receptor was integrated into the genome in multiple copies
and was fused to GFP at the C-terminus and also encoded a
decahistidine tag to enable puriﬁcation. After inclusion of cholesterol
during the puriﬁcation process, active receptor could be puriﬁed in
mg per litre quantities, one of the highest reported yields from any
heterologous system [117].
Table 1
Comparison of GPCR expression systems for NMR.
Expression system Advantages Disadvantages
E. coli Inexpensive Lack of post-translational modiﬁcation e.g. glycosylation is required for
some GPCR-ligand interactions e.g. [181–183]
Ease of culture Lack of some eukaryotic membrane components including cholesterol
can affect receptor activity
Genetic ﬂexibility High level expression may result in formation of inclusion bodies; limited
success in refolding GPCRs [91,184–186]
Strains optimised for protein expression Different codon usage (overcome by expression of rare tRNAs)
Very ﬂexible isotope labelling strategies Low success rate of active GPCR expression
High scalability, although there is not necessarily a linear
relationship between scale and yield
Yeast Inexpensive Endogenous GPCRs and G proteins which may interfere with
expression and puriﬁcation
Ease of culture Different membrane composition
Genetic ﬂexibility Relatively thick cell wall may impede puriﬁcation
Good scalability Labelling strategies more limited than some systems
Cellular compartmentalisation
Eukaryotic post-translational modiﬁcations
Can co-express accessory proteins [187]
Baculovirus/Insect cells Eukaryotic; nearly all post-translational modiﬁcations are
identical to mammalian cells
Glycosylation is different to animal cells
Most GPCRs expressed are active Membrane is higher in unsaturated fatty acids and lower in cholesterol
[188] which can be key in GPCR activity e.g. [189,190]
Insect cells are semi-adherent and also grow in suspension
allowing good scalability e.g. fermenter growths
Requires high virus titre
Commercialisation has reduced costs Cultures are only stable for ~1 month due to accumulation of
defective virus particles
Limited labelling strategies available
Mammalian cells Native cellular environment Relatively expensive
Correct trafﬁcking and folding Possible complications from endogenous receptors and
signalling componentsCorrect membrane environment
Correct post-translational modiﬁcation Difﬁcult to scale
Most GPCRs expressed are active Few labelling strategies available
Cell-free expression Only the protein of interest is produced Poor scalability
Can express toxic proteins Relatively expensive
Can include detergents and membrane mimetics May require optimisation of detergents and membrane mimetics
Yields N1 mg/ml reaction [191] Low success rate of GPCR expression to date [191,192]
Complete labelling control
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expression of proteins. The ability of the yeast to grow in a deﬁned
minimal medium allows uniform labelling with 15N, 13C (e.g. [118]) or
2H [119]. Additionally, amino acid selective labelling is possible [120]
with the advantage that prototrophic P. pastoris strains can be used,
eliminating the drop in protein expression levels normally seen with
auxotrophic strains. Although many of the labelling strategies
available in E. coli can theoretically be applied to P. pastoris,
development of appropriate techniques is not yet complete.
4.4. Baculovirus/insect cells
Insect cells are used in conjunction with a baculovirus which
allows transfection of DNA encoding the GPCR of interest into the cell.
Insect cells such as the commonly used Sf9 cells from Spodoptera
frugiperda have numerous advantages but also some important
disadvantages for GPCR expression (Table 1). Insect cells can produce
levels of GPCRs comparable to other heterologous expression systems.
A comprehensive analysis of expression conditions for sixteen GPCRs
was performed [121] and, although good expression of a number of
receptors was achieved, there was a large degree of variability
between receptors and even for the same receptor in different cell
lines. As with most heterologous expression systems there were no
hard and fast rules as to conditions which were favourable for
expression of active receptor and individual optimisation again
appears key for receptor expression in this system.
Labelling of proteins produced in animal cells is inherently more
complex than in E. coli or yeast. This is largely due to the need for a
deﬁned culture medium which can be supplemented with appropri-
ately labelled precursors and amino acids. However recent advanceshave allowed labelling of certain amino acids [122] and also to
uniformly label entire proteins in quantities suitable for NMR [123].
However, there is still signiﬁcant progress that will have to be made
for the baculovirus/insect cell system to offer the wide range of
labelling strategies available in other systems.
4.5. Mammalian cells
Mammalian cells provide numerous advantages for GPCR expres-
sion (Table 1). However, until recently, heterologous expression of
GPCRs in mammalian cells was largely used for pharmacological and
functional analysis of the receptors and hence was not optimised to
give expression levels suitable for puriﬁcation of signiﬁcant amounts
of protein.
It is possible to express proteins transiently in mammalian cells
(without selection) and also to provide stable expression via a
selective process. However, high-level expression of GPCRs in stable
cell lines can often be toxic. A common strategy for expression of
receptors in mammalian cells is to use Semliki Forest Virus (SFV)
vectors. This has numerous beneﬁts including the ability to generate
rapidly high-titre stocks, a wide range of host cells and good
expression of GPCRs. A recent study used modiﬁed SFV vectors to
express over 100 different GPCRs in mammalian cells lines including
CHO and HEK293 [124]. Approximately 95% of receptors were
expressed in an amount detectable by western blotting with 70%
expressed at a level suitable for biophysical studies. Additional
optimisation of receptor expression was conducted for a number of
receptors, with the adenosine A2a receptor being expressed at
N250 pmol/mg (equivalent to N2 mg per litre) as determined by
ligand binding studies [124]. Although mammalian expression
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are scalable they have the promise to provide suitable concentrations
of active, correctly modiﬁed receptors for biophysical studies.
As mentioned previously, labelling of proteins produced in animal
cells is inhibited by the requirement for difﬁcult-to-make expensive
media. It is possible to uniformly label proteins produced in this
manner [125,126]. It is also possible to label only the backbone
residues of amino acids with 13C, 15N and 2H [127]. Techniques such as
SILAC (Stable Isotope Labelling by Amino Acids in Cell Culture) have
been applied to mammalian cells e.g. [128,129]. In this process,
essential amino acid/s containing the appropriate isotopic label are
included in a cell culture medium which lacks these amino acids and
all proteins produced within the cell incorporate these amino acids.
This can be applied to nearly all types of cells including primary cells
[128].
4.6. Cell-free expression systems
Cell-free expression offers a unique tool in preparation of protein
samples for biophysical studies. The near total control over labelling
strategies allowed by this system, along with other advantages
(Table 1) makes this potentially one of the most signiﬁcant advances
in protein production in recent years (reviewed [130,131]). A key
component of cell-free expression systems is the cell lysate used as the
basis for the reaction mixture. This is commonly from either an E. coli
or eukaryotic source. Whilst the E. coli lysates generally provide a
higher level of protein production, eukaryotic derivatives promote
correct folding of eukaryotic proteins, a signiﬁcant consideration in the
production of GPCRs. The advantages and disadvantages are basically
identical regardless of the source of lysate and are detailed in Table 1.
As mentioned previously, cell-free expression systems have the
highest ﬂexibility of isotopic labelling. As well as incorporation of 15N-
or 13C-labelled amino acids, it is also possible to include a single
labelled amino acid into the reaction mixture. In this case the amino
acid can be labelled either with 15N or 13C. Additionally, it is possible
to label one amino acid with 15N and another with 13C to allow
assignment of pairs of amino acids. Furthermore, by using engineered
tRNAmolecules it is possible to attach a single labelled amino acid at a
speciﬁc position [132]. A strategy of particular interest for membrane
proteins is the speciﬁc labelling of Ala, Phe, Gly, Ile, Leu and Val which
account for ~60% of residues within transmembrane helices [133].
Although most of these techniques have not yet been applied to
GPCRs generated by cell-free expression, it is clear that this system
has massive potential for NMR analysis of such receptors.
4.7. Choosing the right expression system
It is difﬁcult to argue that one system is vastly superior to any other
for expression of GPCRs, each having distinct advantages and dis-
advantages and all systems require some degree of optimisation. If
active receptors can be produced in E. coli this allows labelling and
scalability. However, eukaryotic systems may be required to produce
functional GPCRs, in which case yeast provides a good alternative to E.
coli. Although it is more difﬁcult and expensive to produce large
quantities of labelled protein in insect or mammalian cells, there is a
high likelihood that the receptors will be active. Finally, the future looks
bright for cell-free expression systems which provide the ultimate
control over labelling strategies but are currently limited by scalability
and a low number of GPCRs which have been expressed successfully.
4.8. Ligand expression
It is possible to choose an expression system from the previous
discussion to produce isotopically labelled peptides, but labelling
limitations of the system used must be considered. Most short
peptides have been produced in E. coli. However, short peptides oftenexpress poorly so are normally produced as a fusion with another
protein which can then be cleaved after puriﬁcation.
Some examples of such protein fusion are thioredoxin [134], outer
membrane protein A [135], glutathione S-transferase [136] and the
GB1 domain of Streptococcal protein G [137–139]. It is often desirable
to include a linker region between the fusion protein and the peptide
and also an enzymatic or chemical cleavage tag. Using these methods
it is possible to produce good yields of peptides e.g. 21.5 mg per litre of
GLP1 peptide fused to CMFH domain in rich media [140]. Yields often
drop in minimal media although a yield of 48 mg per litre has been
reported for CMPcc fused to GB1 [137]. One aspect to consider with
the production of fusion proteins is the possible requirement for a free
amino or carboxy terminus for full activity of the ligand. For example,
neurotensin [141] and angiotensin [142] both require a free-COOH
group for maximal activity.
5. Sample environments
Choosing the appropriate environment in which to carry out NMR
studies of GPCRs and their ligands is a critical factor in the generation
of high resolution data. Obtaining homogeneous sample preparations
leads to improved linewidths and therefore spectral resolution, while
heterogeneous samples can result in artifacts such as unexpected
peaks and peak doubling. Protein samples can be prepared in a variety
of states for both solNMR and SSNMR; however, despite numerous
studies no global parameters for sample preparation currently exist.
Therefore, the most suitable conditions for each protein have to be
determined empirically. In terms of GPCRs and their ligands the main
parameters involve the physical state of the sample (e.g. microcrys-
talline/solution), as well as selection of the appropriate solubilising
agent (e.g. detergent micelles/lipid bilayers). Both of these factors can
strongly inﬂuence protein stability and spectral resolution. Below we
summarise the different sample environments that can be applied to
NMR studies of GPCRs and receptor/ligand interactions along with
relevant examples from the literature (see also Fig. 5).
5.1. Detergent micelles and organic solvents
Micellar detergent solutions have been used extensively in NMR
experiments on membrane proteins; and are typically the solubilising
agent of choice in solNMR. In a micelle the hydrophobic regions of the
protein are shielded from the aqueous environment by the surround-
ing detergent molecules thus preventing protein aggregation. Choos-
ing a suitable detergent can be challenging and generally requires a
trial and error approach; some such as DPC and LPPG have gained
more popularity than others (for a detailed assessment of detergents
for solNMR see [143]). While detergents make good solubilising
agents for solNMR they may not mimic closely enough the natural
environment of the protein in the bilayer particularly when
considering oligomer formation and receptor/ligand binding. Fur-
thermore, detergents increase the effective size of the protein
molecule leading to slower tumbling times and subsequent line-
broadening. Slow tumbling times restrict the maximum size of the
protein for structural studies to ~40 kDa, although assignment of
larger proteins has been achieved for example with KcsA [144], Given
this size limitation, studies of GPCRs in micelles have essentially been
limited to small fragments of the proteins, typically containing one or
two transmembrane helices [145–148], although some initial studies
have been attempted with the full-length vasopressin V2 receptor
[149,150]. Furthermore, peptide ligands are often studied in a micelle
environment independently of the receptor such as Leu-5-enkephalin
[151] and dynorphin A [152]. Receptor/ligand interactions however
can be difﬁcult to study in micelles on high-afﬁnity systems (such as
the interaction between neurotensin and its receptor NTS1 Kd of
~1 nM [13,106,153]) as the interaction timescale involved is too fast
for solution measurements.
Fig. 5. Schematic representation of different sample environments for NMR studies of GPCRs.
Fig. 6. Backbone model of the neuropeptide bradykinin when bound to the human G-
protein-coupled bradykinin B2 receptor in DDM determined by SSNMR spectroscopy
at −73 °C. The calculation of the set of 100 superimposed structures was derived from
torsion-angle constraints based on 13C chemical shifts (adapted from [94]with permission
from Copyright owners).
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have been utilized as solubilising agents for membrane proteins with
a smaller size (compared to a protein micelle complex) leading to
more rapid tumbling [13,154–156]. However, in general the biological
relevance of an organic solvent environment is questionable as it may
induce non-native structural rearrangements in the protein, partic-
ularly if there are large extramembranous regions [157,158]. Notable
examples of studies involving GPCRs again are restricted to small
domains including a 73 residue fragment of the yeast pheromone
receptor Ste2p [159], a 40 residue fragment of the human cannabinoid
receptor-1 [160] and the C-terminal of the human β2AR [161].
Although both micelles and organic solvents may not represent a
native environment, protein samples can often be prepared in
micelles at higher concentration particularly compared with lipo-
somes where random orientation can result in approximately half of
the protein unable to bind ligand. Furthermore, solid-state samples
can be easily prepared from micellar solutions simply by freezing (to
below −50 °C) [93,94]. The conformation of bradykinin bound to
human bradykinin B2 receptor in DDM has been recently proposed
[94] (see Fig. 6). Detergents and organic solvents can also form a
crucial parameter in protein reconstitution into lipid bilayers and
precipitation of micro/nanocrystals (see later discussion) for SSNMR
experiments.
The development of novel types of solubilising agents in recent years
such as short amphipathic polymers known as amphipols, along with
reversed micelle systems may provide new possibilities for solNMR
investigations of membrane proteins including GPCRs [162–164].
5.2. Freeze-dried or microcrystalline samples
Lyophilised protein samples were originally required for SSNMR
experiments; however the freeze-drying process is thought to result
in secondary structure alterations leading to rather heterogeneous
samples, which do not yield spectra of high enough resolution for
structural studies [165]. Samples can be partially rehydrated which, in
the case of some soluble proteins such as lysozyme and ubiquitin,
leads to higher spectral resolution [166]. As with other sample
preparation parameters hydration effects must be tested experimen-tally. SSNMR samples can additionally be prepared by simply freezing
the protein containing solution to below−50 °C as in the case of the
neurotensin GPCR ligand. Here, the receptor-bound form of the ligand
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ligand at −80 °C [93].
Micro/nanocrystalline samples of proteins for SSNMR are prepared
by tightly controlled precipitation which often requires extensive
optimisation to obtain samples with narrow linewidths [165]. SSNMR
techniques however, can make use of much smaller lower quality
crystals not accessible to X-ray experiments and have been applied to
a number of studies of soluble proteins [167–170], and the membrane
protein diacylglycerol kinase (DAGK) [171]. As yet no studies of
microcrystalline samples of GPCRs have been reported.
5.3. Lipids
Given that membrane proteins function within a bilayer environ-
ment it is more biologically applicable to be able to carry out
structural investigations in lipids. SSNMR is ideally suited to such
samples, since size limitations with solNMR preclude the use of
bilayers or liposomes. Some membrane proteins can be investigated
directly in cell membrane preparations such as the photoreceptor
bacteriorhodopsin from H. salinarium, where the high receptor
concentration naturally forms ordered 2D crystals. Most membrane
proteins however are not present at such high concentrations in vivo
so crystal formation is typically induced by lipid reconstitution from
micellar solutions; requiring careful optimisation of parameters such
as protein lipid ratio as well as lipid/detergent type [172,173]. Such
crystals allow the protein to be studied in a native environment
preserving structural arrangements which may be critical for regions
involved in ligand binding for example. Proteins reconstituted into
lipid vesicles are amenable to SSNMR studies although investigations
with DAGK and the outer membrane protein G (OmpG) suggest that
vesicles give worse resolution spectra than nanocrystalline or 2D
samples [171,174] (Fig. 7).
Protein samples can be prepared in liposomes and subsequently
deposited on a glass slide, or induced to form bicelles. Both deposited
bilayer ﬁlms and bicelles have the advantage that they can be aligned
in a magnetic ﬁeld which means that orientational constraints can beFig. 7. Effects of sample environments on SSNMR spectra. A: 15N-CP/MAS spectra of 15N-le
spectra of 13C, 15N labelled OmpG reconstituted into lipid vesicles (a) and 2D crystals (b). Ad
samples in crystal forms is better than those of the samples in lipid-reconstituted form.derived (see an example in Fig. 8); useful in both the study of the
membrane protein and also resulting in the alignment of a bound
ligand. Indeed, SSNMR experiments performed in a lipid environment
are ideally suited to investigations of ligand conformation in the
receptor-bound form, a key factor in the development of novel drugs.
Investigations of rhodopsin, CC-chemokine receptor 5 and a fragment
of the human cannabinoid receptor have been undertaken in bilayers
[175–177]; and bound ligand conformation examined with the
neurotensin receptor and the human sweet receptor [93,178].
Bicelles were originally developed in the early 90s [179] and are
mixtures of long-chain and short-chain phospholipids (or sometimes
detergents) which form discrete elongated complexes. The long-chain
lipids make up the planar surface with the short-chain lipids or
detergents forming the curved ends of the bicelle. The extended
planar bilayer region is the main distinguishing feature of a bicelle
over a micelle, resulting in considerable differences in curvature
stress, thus bicelles are expected to represent a more native-like
environment for structural studies [180]. Bicelle size is controlled by
the ratio of long and short lipids (for detailed sample preparation see
[181]), higher ratios of long chained lipid leads to larger bicelles
(500 Å) which can be aligned in a magnetic ﬁeld, while smaller
bicelles (80 Å) result from lower ratios. The ability of large bicelles to
orient in a magnetic ﬁeld can be exploited by SSNMR techniques,
whereas smaller bicelles are suitable for solNMR measurements. This
means that both solNMR and SSNMR measurements can be made in
the same environment allowing for generation of complementary
data and method validation [182–184]. GPCRs including the chemo-
kine receptor (CXCR1) have been successfully reconstituted into
bicelles using a variety of techniques [185–189].
A novel lipid membrane mimetic termed a nanodisc is rapidly
gaining in popularity for NMR applications. Nanodiscs are discoidal
lipid bilayers, smaller than bicelles (20–50 nm), and held together by
a surrounding scaffold protein of high density lipoprotein (for
detailed reviews see [190,191]). These discs provide interesting new
potential for structure determination of membrane proteins indeed
β2AR has recently been incorporated into nanodiscs [192].ucine lipid-reconstituted (a) and nanocrystalline (b) DAGK [171]. B: 13C-CP/MAS NMR
apted from [174] with permission from Copyright owners. The spectral resolution of the
Fig. 8. Structural studies of a GPCR sample in phospholipid bilayers determined by
SSNMR spectroscopy. A: CXCR1model in bilayers. B: 2D PISEMA spectrum of selectively
15N Ile-labelled CXCR1 in magnetically aligned bicelles oriented perpendicular to the
direction of the magnetic ﬁeld. The blue (wheel-like pattern) contours arise from
residues in transmembrane helices, whereas red resonances are from residues in loop
and terminal regions which are likely to have irregular structures (adapted from [186]
with permission from the Copyright owners).
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GPCR structures are still scarce and their resolution is a major
challenge of the membrane structural biology community. Although
the origins of the difﬁculties behind structural studies are becoming
clearer, often through laborious and painstaking characterisations,
this is by no means routine science.
As in many biophysical methods applied to membrane proteins,
expression, biochemical characterisation and labelling (whether Se-Met,
with ﬂuorophores or spin labels, or NMR isotopes) provide their own
challenges even before the method can be implemented, and in many
cases this requires a signiﬁcant investmentof time–oftenyears–which is
incompatible with fast returns.
One reason for crystallisation difﬁculties is the dynamic nature of
GPCRs. Since NMR is well suited to deﬁne dynamics and ranges of
structural constraints, this methodology has the potential to provide
new information either ab initio or to complement crystal models in
which rigid atom structures are deﬁned, although NMR crystallogra-
phy is now becoming a reality [49,51].
Of speciﬁc complementarity is the power of NMR to provide data
on ligand binding, either the kinetic or conformational details, which
may be less well resolved from other direct or indirect methods. Both
solNMR and SSNMR can add this detail for GPCRs [42], but technical
hurdles with suitable sample preparation need to be overcome.
In summary, a combined-front approach is essential if we are to
bring the power of contemporary biophysics to the GPCR ﬁeld in the
hope of understanding their complexity leading eventually to drug
design and then to neurological therapies based on this major class of
receptors.Acknowledgements
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